Literature DB >> 9284147

Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries.

P Amersdorfer1, C Wong, S Chen, T Smith, S Deshpande, R Sheridan, R Finnern, J D Marks.   

Abstract

To produce antibodies capable of neutralizing botulinum neurotoxin type A (BoNT/A), the murine humoral immune response to BoNT/A binding domain (H(C)) was characterized at the molecular level by using phage antibody libraries. Mice were immunized with BoNT/A H(C), the spleens were harvested, and single-chain Fv (scFv) phage antibody libraries were constructed from the immunoglobulin heavy and light chain variable region genes. Phage expressing BoNT/A binding scFv were isolated by selection on immobilized BoNT/A and BoNT/A H(C). Twenty-eight unique BoNT/A H(C) binding scFv were identified by enzyme-linked immunosorbent assay and DNA sequencing. Epitope mapping using surface plasmon resonance in a BIAcore revealed that the 28 scFv bound to only 4 nonoverlapping epitopes with equilibrium constants (Kd) ranging from 7.3 x 10(-8) to 1.1 x 10(-9) M. In a mouse hemidiaphragm assay, scFv binding epitopes 1 and 2 significantly prolonged the time to neuroparalysis, 1.5- and 2.7-fold, respectively, compared to toxin control. scFv binding to epitopes 3 and 4 showed no protection against neuroparalysis. A combination of scFv binding epitopes 1 and 2 had an additive effect on time to neuroparalysis, which increased to 3.9-fold compared to the control. The results suggest that there are two "productive" receptor binding sites on H(C) which lead to toxin internalization and toxicity. Blockade of these two epitopes with monoclonal antibodies may provide effective immunoprophylaxis or therapy against BoNT/A intoxication.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9284147      PMCID: PMC175534          DOI: 10.1128/iai.65.9.3743-3752.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  High efficiency transformation of E. coli by high voltage electroporation.

Authors:  W J Dower; J F Miller; C W Ragsdale
Journal:  Nucleic Acids Res       Date:  1988-07-11       Impact factor: 16.971

2.  Direct clone characterization from plaques and colonies by the polymerase chain reaction.

Authors:  D Güssow; T Clackson
Journal:  Nucleic Acids Res       Date:  1989-05-25       Impact factor: 16.971

3.  An Hsp70-like protein in the ER: identity with the 78 kd glucose-regulated protein and immunoglobulin heavy chain binding protein.

Authors:  S Munro; H R Pelham
Journal:  Cell       Date:  1986-07-18       Impact factor: 41.582

4.  Canonical structures for the hypervariable regions of immunoglobulins.

Authors:  C Chothia; A M Lesk
Journal:  J Mol Biol       Date:  1987-08-20       Impact factor: 5.469

5.  A method for isolation of intact, translationally active ribonucleic acid.

Authors:  G Cathala; J F Savouret; B Mendez; B L West; M Karin; J A Martial; J D Baxter
Journal:  DNA       Date:  1983

6.  Radioiodination of botulinum neurotoxin type A with retention of biological activity and its binding to brain synaptosomes.

Authors:  R S Williams; C K Tse; J O Dolly; P Hambleton; J Melling
Journal:  Eur J Biochem       Date:  1983-03-15

7.  Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.

Authors:  J S Huston; D Levinson; M Mudgett-Hunter; M S Tai; J Novotný; M N Margolies; R J Ridge; R E Bruccoleri; E Haber; R Crea
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

8.  Equine antitoxin use and other factors that predict outcome in type A foodborne botulism.

Authors:  C O Tacket; W X Shandera; J M Mann; N T Hargrett; P A Blake
Journal:  Am J Med       Date:  1984-05       Impact factor: 4.965

9.  Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E.

Authors:  C H Hatheway; J D Snyder; J E Seals; T A Edell; G E Lewis
Journal:  J Infect Dis       Date:  1984-09       Impact factor: 5.226

10.  Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves.

Authors:  J D Black; J O Dolly
Journal:  J Cell Biol       Date:  1986-08       Impact factor: 10.539

View more
  40 in total

1.  High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A.

Authors:  D D Pless; E R Torres; E K Reinke; S Bavari
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

2.  Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display.

Authors:  B P Mullaney; M G Pallavicini; J D Marks
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

3.  Characterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity.

Authors:  Christelle Mazuet; Julie Dano; Michel R Popoff; Christophe Créminon; Hervé Volland
Journal:  PLoS One       Date:  2010-08-26       Impact factor: 3.240

4.  Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization.

Authors:  T J Smith; J Lou; I N Geren; C M Forsyth; R Tsai; S L Laporte; W H Tepp; M Bradshaw; E A Johnson; L A Smith; J D Marks
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

5.  Comparing CDRH3 diversity captured from secondary lymphoid organs for the generation of recombinant human antibodies.

Authors:  Sophie Venet; Marie Kosco-Vilbois; Nicolas Fischer
Journal:  MAbs       Date:  2013-07-02       Impact factor: 5.857

6.  DNA vaccines targeting heavy chain C-terminal fragments of Clostridium botulinum neurotoxin serotypes A, B, and E induce potent humoral and cellular immunity and provide protection from lethal toxin challenge.

Authors:  Veronica L Scott; Daniel O Villarreal; Natalie A Hutnick; Jewell N Walters; Edwin Ragwan; Khalil Bdeir; Jian Yan; Niranjan Y Sardesai; Adam C Finnefrock; Danilo R Casimiro; David B Weiner
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.

Authors:  R Levy; C M Forsyth; S L LaPorte; I N Geren; L A Smith; J D Marks
Journal:  J Mol Biol       Date:  2006-10-03       Impact factor: 5.469

8.  Development of an ELISA microarray assay for the sensitive and simultaneous detection of ten biodefense toxins.

Authors:  Kathryn L Jenko; Yanfeng Zhang; Yulia Kostenko; Yongfeng Fan; Consuelo Garcia-Rodriguez; Jianlong Lou; James D Marks; Susan M Varnum
Journal:  Analyst       Date:  2014-08-12       Impact factor: 4.616

9.  Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.

Authors:  A Nowakowski; C Wang; D B Powers; P Amersdorfer; T J Smith; V A Montgomery; R Sheridan; R Blake; L A Smith; J D Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

10.  Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies.

Authors:  Anne-Laure Goenaga; Yu Zhou; Christine Legay; Houcine Bougherara; Lan Huang; Bin Liu; Daryl C Drummond; Dmitri B Kirpotin; Christian Auclair; James D Marks; Marie-Alix Poul
Journal:  Mol Immunol       Date:  2007-05-10       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.